MSR41 Matching-Adjusted Indirect Comparison of Amivantamab Vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
Jul 1, 2022, 00:00
10.1016/j.jval.2022.04.1248
https://www.valueinhealthjournal.com/article/S1098-3015(22)01449-8/fulltext
Title :
MSR41 Matching-Adjusted Indirect Comparison of Amivantamab Vs. Mobocertinib in EGFR Exon 20 Insertion-Mutated Non-Small Cell Lung Cancer
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(22)01449-8&doi=10.1016/j.jval.2022.04.1248
First page :
Section Title :
Open access? :
No
Section Order :
11117